Literature DB >> 18265407

Absence of cutaneous neurofibromas in an NF1 patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region.

Hildegard Kehrer-Sawatzki1, Eva Schmid, Carsten Fünsterer, Lan Kluwe, Victor-Felix Mautner.   

Abstract

The majority of neurofibromatosis type 1 (NF1) microdeletions in 17q11.2 span approximately 1.4 Mb and have breakpoints that lie within the proximal and distal NF1-low copy repeats, termed NF1-REPs. Less frequent are patients with atypical deletions and non-recurring breakpoints. NF1 patients with gross deletions have been reported to manifest a more severe clinical phenotype than NF1 patients with intragenic mutations, and display early onset and extensive growth of neurofibromas. It has been suggested that the deletion of a neighboring gene or genes in addition to the NF1 gene may modify the expression of the disease, particularly with regard to the high burden of cutaneous neurofibromas. Thus, atypical deletions partially overlapping with the common 1.4 Mb microdeletion interval could prove useful in identifying possible genetic modifiers in the NF1 gene region whose haploinsufficiency might promote neurofibroma growth. Here we report a 20-year-old female who has an atypical deletion with a proximal breakpoint in NF1 intron 21 and a distal deletion breakpoint in the ACCN1 gene. The deletion spans 2.7 Mb and was mediated by an intrachromosomal non-homology-driven mechanism, for example, non-homologous end-joining (NHEJ). Remarkably, this patient did not exhibit cutaneous neurofibromas. However, genotype-phenotype comparisons in this and other previously reported patients with atypical deletions partially overlapping the commonly deleted 1.4 Mb interval do not identify a specific deleted region that is associated with increased neurofibroma growth. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18265407     DOI: 10.1002/ajmg.a.32045

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

1.  Identification of an atypical microdeletion generating the RNF135-SUZ12 chimeric gene and causing a position effect in an NF1 patient with overgrowth.

Authors:  Luca Ferrari; Giulietta Scuvera; Arianna Tucci; Donatella Bianchessi; Francesco Rusconi; Francesca Menni; Elena Battaglioli; Donatella Milani; Paola Riva
Journal:  Hum Genet       Date:  2017-08-03       Impact factor: 4.132

Review 2.  On the sequence-directed nature of human gene mutation: the role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease.

Authors:  David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen
Journal:  Hum Mutat       Date:  2011-09-02       Impact factor: 4.878

3.  Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions.

Authors:  Hildegard Kehrer-Sawatzki; Julia Vogt; Tanja Mußotter; Lan Kluwe; David N Cooper; Victor-Felix Mautner
Journal:  Neurogenetics       Date:  2012-05-13       Impact factor: 2.660

Review 4.  Emerging genotype-phenotype relationships in patients with large NF1 deletions.

Authors:  Hildegard Kehrer-Sawatzki; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2017-02-17       Impact factor: 4.132

Review 5.  Atypical NF1 Microdeletions: Challenges and Opportunities for Genotype/Phenotype Correlations in Patients with Large NF1 Deletions.

Authors:  Hildegard Kehrer-Sawatzki; Ute Wahlländer; David N Cooper; Victor-Felix Mautner
Journal:  Genes (Basel)       Date:  2021-10-19       Impact factor: 4.096

6.  Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.

Authors:  Tanja Mußotter; Lan Kluwe; Josef Högel; Rosa Nguyen; David N Cooper; Victor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  BMC Med Genet       Date:  2012-10-26       Impact factor: 2.103

Review 7.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.